RESUMO
ABSTRACT Introdution: The National Reference Laboratory (LRN) in Tuberculosis (TB) is a laboratory unit of highly specialized technical excellence that has developed projects involving training in human resources and the enhancement of techniques essential for the diagnosis of TB. Its purpose is the continuous improvement of all laboratory processes and their quality management, with the purpose of collaborating on and strengthening the actions in the network that integrate it in the aid of surveillance and in the fight against TB. Objectives: This research aims to describe the quality indicators that were defined through the process mapping methodology, with the objective of promoting and raising the level of quality and reliability of the different laboratory processes performed at LRN in TB. Method: For the definition of indicators, process mapping was used which, through flow charts, can establish and determine the most appropriate indicators for LRN in TB. After defining these indicators, they were described with their respective titles, preventive and corrective measures, importance and goals. Results: The results of the research suggest that the established indicators are fundamental for the laboratory processes, since they improve quality management. Conclusion: Through this study, we seek to encourage and impel the managers involved in the field of TB and in the field of health on the utility and the need to control and measure processes, being able to standardize them with the help of indicators or other quality tools.
RESUMO Introdução: O Laboratório de Referência Nacional (LRN) em Tuberculose (TB) é uma unidade laboratorial de excelência técnica altamente especializada que tem desenvolvido projetos envolvendo a capacitação de recursos humanos e o aprimoramento de técnicas fundamentais para o diagnóstico da TB. Seu propósito é a melhoria contínua de todos os processos laboratoriais e a sua gestão da qualidade, com o intuito de colaborar e fortalecer as ações na rede que o integram no auxílio à vigilância e no combate da TB. Objetivos: Esta pesquisa tem a finalidade de descrever os indicadores da qualidade que foram definidos por meio do método de mapeamento de processos, com o objetivo de promover e elevar o nível da qualidade e da confiabilidade dos diferentes processos laboratoriais realizados no LRN em TB. Método: Para a definição dos indicadores, foi utilizado o mapeamento de processos que, por meio de fluxogramas, pode estabelecer e determinar os indicadores mais adequados para o LRN em TB. Após a definição desses indicadores, eles foram descritos com seus respectivos títulos, medidas preventivas e corretivas, importância e metas. Resultados: Os resultados da pesquisa sugerem que os indicadores estabelecidos são fundamentais para os processos do laboratório, visto que melhoram a gestão da qualidade. Conclusão: Por intermédio deste estudo, buscamos incentivar e impulsionar os gestores envolvidos no campo da TB e no campo da saúde sobre a utilidade e a necessidade de controlar e medir os processos, podendo padronizá-los com a ajuda dos indicadores ou outras ferramentas da qualidade.
RESUMO
α-Thalassemia (α-thal) is a hereditary hemoglobinopathy characterized by microcytic anemia due to impaired production of α chains of human globin. Brazilian studies show that the most common genotype is an -α(3.7) deletion with the loss of one or two α genes. As the production of α chains is not as accentuated in these cases, the correct diagnosis can only be achieved through molecular analysis that is not usually routinely performed by laboratories. We investigated the occurrence of α-thal babies born between September 2011 to January 2013 at the hospital of the Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, Brazil, and blood donors of the Uberaba Regional Blood Center, Hemominas Foundation, Uberaba, Brazil, correlating it with ethnicity and differences between hematological parameters of donors, α-thal and iron deficiency patients. α-Thalassemia was investigated for the most common deleted alleles (-α(3.7), -α(4.2), - -(SEA), - -(FIL), - -(THAI), -(α)(20.5) and - -(MED)). The incidence in newborns was 13.16% with a predominance of heterozygosity for the -α(3.7) genotype (12.35%), followed by the -α(3.7)/-α(3.7) (0.46%) and αα/-α(4.2) genotypes (0.35%). In blood donors, the prevalence of α-thal was 14.89%, with all cases being heterozygous for the -α(3.7) deletion. There was an association of the α-thal genotype with African ancestors for both groups, thereby confirming published data and showing the strong influence of Blacks on the composition of the population of Brazil's southeastern region. Minor changes were found between hematological parameters of blood donors with iron deficiency and α-thal that did not contribute to the differential diagnosis between the two types of anemia.
Assuntos
Genótipo , alfa-Globinas/genética , Talassemia alfa/epidemiologia , Talassemia alfa/genética , Alelos , Anemia Ferropriva/sangue , Anemia Ferropriva/diagnóstico , Anemia Ferropriva/epidemiologia , Brasil/epidemiologia , Brasil/etnologia , Diagnóstico Diferencial , Índices de Eritrócitos , Frequência do Gene , Humanos , Incidência , Recém-Nascido , Talassemia alfa/sangue , Talassemia alfa/diagnósticoRESUMO
Embora estejam bem definidos os benefícios da implantação do programa de triagem neonatal para hemoglobinopatias, não são raros os estudos que apontam falhas nesses programas. Este estudo teve como objetivo avaliar o programa de triagem neonatal para hemoglobinopatias no município de Dourados, estado do Mato Grosso do Sul (MS). Foram entrevistadas, através da aplicação de formulários, 32 famílias cujos filhos foram identificados como portadores de hemoglobinopatias, durante a triagem neonatal, no período de janeiro de 2000 a dezembro de 2005. Adicionalmente, foram verificadas a cobertura do Programa Nacional de Triagem Neonatal (PNTN) e a incidência de hemoglobinopatias no MS, de 2000 a 2005. Dos 242 casos de hemoglobinopatias diagnosticados neste período, a heterozigose para hemoglobina S demonstrou incidência de 1,37 por cento, a heterozigose para hemoglobina C, 0,37 por cento e a heterozigose para hemoglobina D, 0,007 por cento. Não foram diagnosticados casos de anemia falciforme. A cobertura encontrada foi de 81,4 por cento. Foram detectadas falhas, como a não reconvocação para o exame confirmatório, ausência de encaminhamento médico para orientação, falta de investigação familiar e a falha na compreensão do aconselhamento genético.
Although the benefits of implanting a neonatal screening program for hemoglobinopathies are well defined, there are many studies that point to failures in these programs. The objective of this study was to evaluate the efficiency of the neonatal screening program for hemoglobinopathies in the municipality of Dourados, in the state of Mato Grosso do Sul, Brazil. Between January 2000 and December 2005, thirty-two families with children diagnosed during neonatal screening as having hemoglobinopathies were evaluated using questionnaires. Additionally, the coverage of the Brazilian National Neonatal Screening Program and the incidence rates of hemoglobinopathies in the state of Mato Grosso do Sul between 2000 and 2005 were analyzed. Of the 242 cases of hemoglobinopathies that were diagnosed in this period, 1.37 percent individuals were identified as heterozygotes for hemoglobin S, 0.37 percent for hemoglobin C, and 0.07 percent for hemoglobin D. There were no cases of sickle cell anemia diagnosed during this period. The program was found to be positive and provided a broad coverage of 81.4 percent. Some failures were detected such as not requiring patients to return for confirmation examinations, the lack of medical counseling and follow through, lack of investigations of family histories, and lack of understanding on the part of the family of the genetic counseling they received.
